Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea
1
Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 13620, Korea
2
Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Korea
*
Author to whom correspondence should be addressed.
†
These authors made an equal contribution as co-first authors.
Academic Editor: Philip P. Foster
J. Pers. Med. 2021, 11(2), 116; https://doi.org/10.3390/jpm11020116
Received: 27 January 2021 / Revised: 5 February 2021 / Accepted: 6 February 2021 / Published: 10 February 2021
(This article belongs to the Special Issue COVID-19 Related Complications)
We aimed to investigate whether statin therapy is associated with the incidence of coronavirus disease 2019 (COVID-19) among the South Korean population. In addition, we examined whether statin therapy affects hospital mortality among COVID-19 patients. The National Health Insurance Service (NHIS)-COVID-19 database in South Korea was used for data extraction for this population-based cohort study. A total of 122,040 adult individuals, with 22,633 (18.5%) in the statin therapy group and 101,697 (91.5%) in the control group, were included in the analysis. Among them, 7780 (6.4%) individuals were diagnosed with COVID-19 and hospital mortality occurred in 251 (3.2%) COVID-19 cases. After propensity score matching, logistic regression analysis showed that the odds of developing COVID-19 were 35% lower in the statin therapy group than in the control group (odds ratio: 0.65, 95% confidence interval: 0.60 to 0.71; p < 0.001). Regarding hospital mortality among COVID-19 patients, the multivariable model indicated that there were no differences between the statin therapy and control groups (odds ratio: 0.74, 95% confidence interval: 0.52 to 1.05; p = 0.094). Statin therapy may have potential benefits for the prevention of COVID-19 in South Korea. However, we found that statin therapy does not affect the hospital mortality of patients who are diagnosed with COVID-19.
View Full-Text
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
- Supplementary File 1:
PDF-Document (PDF, 122 KiB)
MDPI and ACS Style
Oh, T.K.; Song, I.-A.; Jeon, Y.-T. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea. J. Pers. Med. 2021, 11, 116. https://doi.org/10.3390/jpm11020116
AMA Style
Oh TK, Song I-A, Jeon Y-T. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea. Journal of Personalized Medicine. 2021; 11(2):116. https://doi.org/10.3390/jpm11020116
Chicago/Turabian StyleOh, Tak K.; Song, In-Ae; Jeon, Young-Tae. 2021. "Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea" J. Pers. Med. 11, no. 2: 116. https://doi.org/10.3390/jpm11020116
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit